Addex Pharmaceuticals / Addex First Half 2010 Financial Results Next Wednesday est traité et transmis par Hugin AS. L''émetteur est uniquement responsable du contenu de ce communiqué de presse. 

Geneva,   Switzerland,  July  21, 2010 -  Allosteric  modulation  company  Addex
Pharmaceuticals Ltd. (SIX:ADXN) will discuss its financial results for the first
half  of 2010 and  update the  status of  key products  in development  during a
teleconference  and webcast for investors, analysts  and the media on Wednesday,
July 28 at 16:00 CET (15:00 BST/10:00 EST).

Addex  last updated its pipeline status during  its R&D Day on May 11, 2010. The
slides   and   recorded   webcasts   from   the   R&D   Day   are  available  at
www.addexpharma.com.

Title:                Addex First Half 2010 Financial Results Conference Call

Date:               July 28, 2010


Time:                 16:00 CET (15:00 BST/10:00 EST)


Dial-in numbers:      +41 91 610 56 00 (Europe)
                    +44 207 107 0611 (UK)
                    +1 866 291 4166 (USA)

The live webcast and slides, as well as the webcast replay and transcript, will
be available atwww.addexpharma.com.

Addex  Pharmaceuticals (www.addexpharma.com)  discovers and  develops allosteric
modulators  for human health and is focused on validated therapeutic targets for
diseases  of the central  nervous system, metabolic  disorders and inflammation.
Subject  to the completion of Phase I testing and regulatory approvals, Phase II
clinical  trials are expected to start in  2010 in four indications for two lead
products:  ADX48621, an mGluR5 negative  allosteric modulator (NAM), in dystonia
and  Parkinson's disease levodopa-induced dyskinesia  (PD-LID); and ADX71149, an
mGluR2  positive  allosteric  modulator  (PAM),  in  schizophrenia  and anxiety.
ADX71149  is  licensed  to  Ortho-McNeil-Janssen  Pharmaceuticals  Inc.  A third
product,  ADX71943,  GABA-B  receptor  PAM  with  potential for chronic pain, is
scheduled  to enter Phase I testing around the end of 2010. In addition, Merck &
Co.,  Inc.  has  licensed  rights  to  two  preclinical products: mGluR4 PAM for
Parkinson's  disease and  mGluR5 PAM  for schizophrenia.  Additional preclinical
discovery  stage programs  include: mGluR2  NAM, GLP1R  PAM, IL1R1 NAM and TNFR1
NAM.  Roche Venture Fund  and SR-One, corporate  venture arm of GlaxoSmithKline,
are investors in Addex.


Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos@addexpharma.com



Disclaimer:  The foregoing  release may  contain forward-looking statements that
can   be  identified  by  terminology  such  as  "not  approvable",  "continue",
"believes",  "believe", "will", "remained open  to exploring", "would", "could",
or  similar expressions,  or by  express or  implied discussions regarding Addex
Pharmaceuticals  Ltd, its  business, the  potential approval  of its products by
regulatory  authorities,  or  regarding  potential  future  revenues  from  such
products.  Such forward-looking  statements reflect  the current  views of Addex
Pharmaceuticals  Ltd  regarding  future  events,  future economic performance or
prospects,  and, by their very nature, involve inherent risks and uncertainties,
both  general and  specific, whether  known or  unknown, and/or any other factor
that  may materially differ from  the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5,  mGluR7 or other therapeutic targets to be materially different from any
future  results,  performance  or  achievements  expressed  or  implied  by such
statements.  There can  be no  guarantee that  allosteric modulators  of mGluR2,
mGluR4,  mGluR5,  mGluR7  will  be  approved  for  sale  in any market or by any
regulatory  authority. Nor can there be any guarantee that allosteric modulators
of  mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management's
expectations  regarding  allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or  other  therapeutic  targets  could  be  affected  by,  among  other  things,
unexpected  actions by our partners, unexpected  regulatory actions or delays or
government  regulation generally;  unexpected clinical  trial results, including
unexpected  new  clinical  data  and  unexpected additional analysis of existing
clinical  data; competition in general;  government, industry and general public
pricing  pressures; the company's ability to  obtain or maintain patent or other
proprietary  intellectual property protection. Should one or more of these risks
or  uncertainties materialize, or should underlying assumptions prove incorrect,
actual  results may vary materially  from those anticipated, believed, estimated
or  expected. Addex  Pharmaceuticals Ltd  is providing  the information  in this
press  release as of this  date and does not  undertake any obligation to update
any  forward-looking statements contained  in this press  release as a result of
new  information,  future  events  or  otherwise,  except  as may be required by
applicable laws.


[HUG#1433038]



 --- Fin de Message --- 

Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz

ISIN: CH0029850754;




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. 
The owner of this announcement warrants that: 
	(i) the releases contained herein are protected by copyright and other applicable laws; and 
	(ii) they are solely responsible for the content, accuracy and originality of the information contained therein. 
All reproduction for further distribution is prohibited.
		
Source: Addex Pharmaceuticals via Thomson Reuters ONE